Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study of the Efficacy and Safety of Intratumoral Injection of Toluenesulfonamide (PTS) in Combination With or Without First-line Chemoimmunotherapy Based on Standard Treatment for Stage IV Driver Gene-negative Non-small Cell Lung Cancer

NCT06607796 is registered in ClinicalTrials.gov with Zhou Chengzhi as lead sponsor.

NCT NCT06607796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study of the Efficacy and Safety of Intratumoral Injection of Toluenesulfonamide (PTS) in Combination With or Without First-line Chemoimmunotherapy Based on Standard Treatment for Stage IV Driver Gene-negative Non-small Cell Lung Cancer
Lead sponsor
Zhou Chengzhi
Phase
Phase 3
Overall status
Recruiting
Start date
March 1, 2024
Completion date
December 31, 2026
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer